No longer limited by yesterday’s knowledge and technology, our simple, promising science has attracted some of the boldest and most accomplished leaders from across the medical industry.

Our years of research, deep expertise and personal connections to this mission have positioned us to move this incredible breakthrough forward.


Hans Sollinger, MD, PhD, Dr hc Founder & Interim CSO
A world leader in diabetes care for decades, who has earned numerous awards for contributions that have revolutionized the field. More details »

Eric Spyra President & Interim CEO
Experienced investor with a strong development background and unique connection to Dr. Sollinger’s work. More info »

Tausif Alam, PhD Research
Molecular scientist who engineered ENDSULIN’s groundbreaking DNA sequence. More info »

Gary Mansfield, PhD Development
20+ years of experience in cell and gene therapy product development, and part of the team that pioneered one of the first RNA editing platforms. More info »

Adam Bock, PhD Interim CFO
Award-winning academic, venture financier, and entrepreneur who has successfully co-founded 4 life science companies. More info »

Sam Adams Director of Corporate Development
Development and marketing leader who has led two health technology companies from concept to the clinic. More info »

Patricia Williams, PhD
Regulatory Affairs and Compliance

Ginger Gant
Executive Administrator

Tina Kaur
Study Monitor

Dylan Schwitzer
Corporate Development Associate


Thomas J. Dee, MBA Board member
Entrepreneurial biotech CFO who helped break one of the first FDA-approved gene therapies onto the market. More info »

Elizabeth Aden, PhD Board member
Strategic Marketing and Business Development Consultant, SPARK Advisor at Stanford University and Co-Founder of Circuit Therapeutics. More info »


Peter Thule, MD Scientific Advisory Board member
World-renowned endocrinologist, and the only other researcher with in-depth experience looking at this type of gene alteration in hepatocytes. More info »